Christoph Pohl

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

Ludwig Kappos, Chris H. Polman, Mark S. Freedman et al. · American Journal of Ophthalmology · 2006 · 551 citations

Life Sciences, Neurology, Pharmacotherapy +12

Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression

Alberto Ascherio, Kassandra L. Munger, Rick White et al. · JAMA Neurology · 2014 · 512 citations

Medicine, Neurology, Pharmacotherapy +17

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

Ludwig Kappos, Mark S. Freedman, Chris H. Polman et al. · The Lancet · 2007 · 501 citations

Life Sciences, Neurology, Neuroimmunology +9

Silent and apparent cerebral embolism after retrograde catheterisation of the aortic valve in valvular stenosis: a prospective, randomised study

Heyder Omran, Harald Schmidt, M. H. Hackenbroch et al. · The Lancet · 2003 · 417 citations

Medicine, Cardiology, Surgery +13

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

Paul O’Connor, Massimo Filippi, Barry G.W. Arnason et al. · The Lancet Neurology · 2009 · 403 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +8